AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.
Can Large Language Models Solve More Rare Disease Genomes?
LLM-assisted rare disease re-assessment improves genomic analysis, increasing diagnostic yield and supporting clinician-led precision medicine and possibly drug development.
AI Bioweapons Risk: What Anthropic’s Report Means for Pharma
The Anthropic 2026 threat report documents a significant bioweapons risk. See what this means for pharma biosecurity, research, and AI controls.
AI Creates New Viruses? Not Quite. AI-Designed Bacteriophages
AI-designed bacteriophages show how genome models could create new antibacterial therapies while forcing pharma to rethink biological AI governance and biosecurity.
Ketryx and Accenture Build Regulated AI MedTech at Scale
Ketryx and Accenture are combining AI-native compliance infrastructure and transformation expertise to help MedTech scale regulated AI without slowing development.
How AI Is Reshaping Data Integrity in Pharma Manufacturing
Veragence CEO Nour AlSaleh discusses how AI is transforming data integrity in pharma manufacturing, regulatory compliance, the "human-in-the-loop" requirement, and patient safety in the era of AI-driven GxP systems.